MedTrace Logo

Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19

NCT04420299 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2022-06-07

No results posted yet for this study

Summary

The 2019 coronavirus disease (Covid-19) is a new disease caused by the SARS-CoV2 virus of which many things are not yet known. Among others, there is a need to define the best therapeutic strategy to treat Covid-19, improving patients survival and reducing complications in its management, for which many different types of treatments are being tested.

The drug being tested in this clinical trial is called bemiparin. Bemiparin is a drug authorized as a prevention and as a treatment for deep vein thrombosis (blood clots in one or more veins, generally in the legs) and venous thromboembolism (when the clot can detach and lodge in other organs such as the lungs). Covid-19 patients have been shown to be at increased risk of developing clotting problems such as those described above.

In this context, this clinical trial is being carried out to find out if certain doses of bemiparin can contribute to better management of the disease.

Conditions

Interventions

DRUG

Bemiparin

Bemiparin at therapeutic dose for 10 days

DRUG

Bemiparin

Bemiparin at prophylactic dose for 10 days

Sponsors & Collaborators

  • Syntax for Science, S.L

    collaborator INDUSTRY

  • Fundación de investigación HM

    lead OTHER

Principal Investigators

  • Antonio Cubillo, MD · Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-04
Primary Completion
2021-06-08
Completion
2021-06-08

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420299 on ClinicalTrials.gov